President Barack Obama has proposed a budget for the 2013 fiscal year that largely keeps growth slow and steady for key biopharma agencies, with exceptions. FDA would see its budgetary authority inch up by 0.4% to $2.517 billion. But when industry user fees are included, FDA’s total program spending would jump 17% to $4.486 billion. CDC would see its discretionary budget authority shrink by 11.6% or $664 million to $5.068 billion. After nondiscretionary spending is factored in, however, total CDC funding rises by 0.4% to $11.236 billion in FY ’13. What do you think?
How helpful do you think President Obama’s proposed budget for the next fiscal year is to FDA and CDC?